About Immodulon

Gertjan is a global biotech leader with over 25 years’ industry experience in finance, business development and operations. Most recently, Gertjan was CEO of VICO Therapeutics BV, a privately held Netherlands based company. Prior to VICO, Gertjan spent 12 years at Celgene where he started as part of their initial European management team Based in Switzerland. As a member of their New Jersey based corporate business development team, he played a key role in the acquisition of Abraxis BioScience, adding Abraxane to Celgene’s portfolio. He started his career at Amgen and over a 9 year period held various roles at their European (Switzerland) and corporate headquarters in the U.S.

Gertjan holds a MSc in Economics from Maastricht University, Netherlands.

Peter is a highly experienced business development executive, with over 20 years’ international industry expertise. Previously, Peter served as Head of Corporate Development at ADC Therapeutics where he played an integral role transforming the company from a private R&D biotech to a NYSE listed public biotech with a commercial therapeutic product. Prior to ADC Therapeutics, Peter spent 12 years at Celgene in a number of roles of increasing responsibility in Switzerland and the US across medical, commercial and business development and played a key role integrating Abraxane into the Celgene portfolio. Peter began his career as a Preclinical Senior Scientist at Apoxis.

Peter holds a BSc in Cell Biology from the University of East Anglia and a PhD in Molecular and Cellular Biology from the University of Nottingham.

Richard brings over 30 years’ pharmaceutical experience across regulatory, drug development and commercialisation to Immodulon. He spent 15 years at Celgene, most recently as Vice President, Global Regulatory CMC before founding R3LS, a CMC consultancy. At Celgene, Richard built and led the Global Regulatory CMC group responsible for developing and implementing CMC strategies for small molecules, biologics and cell therapies. During his time, he oversaw the development of 20 clinical compounds from Phase 1 clinical development through to commercialisation.

Richard started his career at Merck & Co., Inc in Analytical & Quality Services before transitioning to a regulatory CMC position. He holds an MSc in Chemistry from Lehigh University and a BSc in Chemistry from Ohio University.

Owen is a highly experienced regulatory affairs leader with over 30 years’ global experience in the pharmaceutical industry. Owen has led regulatory teams across all phases of clinical development and has a proven track record in obtaining and expanding marketing authorisations for multiple new therapeutics. He joins Immodulon from 4D Pharma where he served as Senior Vice President, Regulatory Affairs & Quality Assurance. Owen has also held senior regulatory roles at Alnylam Pharmaceuticals, Taiho Oncology, Celgene and Johnson and Johnson.

Owen began his career as a Research Scientist. He holds a PhD and BSc in Chemistry from Imperial College London and holds a diploma in regulatory affairs from the University of Wales, Cardiff.